MX2020002032A - Inhibidores de bcl-2. - Google Patents

Inhibidores de bcl-2.

Info

Publication number
MX2020002032A
MX2020002032A MX2020002032A MX2020002032A MX2020002032A MX 2020002032 A MX2020002032 A MX 2020002032A MX 2020002032 A MX2020002032 A MX 2020002032A MX 2020002032 A MX2020002032 A MX 2020002032A MX 2020002032 A MX2020002032 A MX 2020002032A
Authority
MX
Mexico
Prior art keywords
sub
bcl
inhibitors
disease
compounds
Prior art date
Application number
MX2020002032A
Other languages
English (en)
Inventor
Yan Lou
Yi Chen
Original Assignee
Guangzhou Lupeng Pharmaceutical Company Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Lupeng Pharmaceutical Company Ltd filed Critical Guangzhou Lupeng Pharmaceutical Company Ltd
Publication of MX2020002032A publication Critical patent/MX2020002032A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/76—Chemiluminescence; Bioluminescence
    • G01N21/763—Bioluminescence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Plasma & Fusion (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La descripcion incluye compuestos de Formula (A): (ver Fórmula A) en donde R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, y R12, j, k, m, n, Y, W, W1, W2, W3, V, L, Z1, Q1, Q2, Q3, y Q4, se definen en la presente; también se describe un método para tratar una enfermedad neoplasica, una enfermedad autoinmune o una enfermedad neurodegenerativa con estos compuestos.
MX2020002032A 2017-08-23 2018-08-22 Inhibidores de bcl-2. MX2020002032A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762549081P 2017-08-23 2017-08-23
US201862615007P 2018-01-09 2018-01-09
PCT/US2018/047444 WO2019040573A1 (en) 2017-08-23 2018-08-22 INHIBITORS OF BCL-2

Publications (1)

Publication Number Publication Date
MX2020002032A true MX2020002032A (es) 2020-09-17

Family

ID=63490700

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020002032A MX2020002032A (es) 2017-08-23 2018-08-22 Inhibidores de bcl-2.
MX2020002033A MX2020002033A (es) 2017-08-23 2018-08-22 Derivados heterociclicos condensados como inhibidores de bcl-2 para el tratamiento de enfermedades neoplasticas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020002033A MX2020002033A (es) 2017-08-23 2018-08-22 Derivados heterociclicos condensados como inhibidores de bcl-2 para el tratamiento de enfermedades neoplasticas.

Country Status (14)

Country Link
US (5) US11279711B2 (es)
EP (3) EP4227311A1 (es)
JP (2) JP7467332B2 (es)
KR (2) KR102680163B1 (es)
CN (4) CN116621860A (es)
AU (2) AU2018322059C1 (es)
CA (2) CA3073446A1 (es)
DK (2) DK3672975T3 (es)
ES (2) ES2971457T3 (es)
FI (2) FI3672976T3 (es)
IL (1) IL272762B2 (es)
MX (2) MX2020002032A (es)
SG (1) SG11202001553UA (es)
WO (2) WO2019040550A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2971457T3 (es) * 2017-08-23 2024-06-05 Guangzhou Lupeng Pharmaceutical Company Ltd Inhibidores de BCL-2
CA3098348A1 (en) 2018-04-29 2019-11-07 Beigene, Ltd. Bcl-2 inhibitors
US11903950B2 (en) * 2018-08-22 2024-02-20 Newave Pharmaceutical Inc. BCL-2 inhibitors
WO2020140005A2 (en) 2018-12-29 2020-07-02 Newave Pharmaceutical Inc. Bcl-2 inhibitors
US20220372042A1 (en) 2019-10-03 2022-11-24 Newave Pharmaceutical Inc. Condensed heterocycles as bcl-2 inhibitors
EP4051676A4 (en) * 2019-10-28 2023-11-22 BeiGene, Ltd. BCL-2 INHIBITORS
WO2021133817A1 (en) 2019-12-27 2021-07-01 Guangzhou Lupeng Pharmaceutical Company Ltd. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
CN115484933A (zh) * 2020-02-24 2022-12-16 广州麓鹏制药有限公司 含有bcl2抑制剂的热熔挤出固体分散体
WO2022140224A1 (en) 2020-12-22 2022-06-30 Newave Pharmaceutical Inc. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
CN113694059B (zh) * 2021-03-24 2023-09-26 浙江大学 Nl101在制备治疗急性、慢性排斥反应药物中的应用
WO2023121713A1 (en) * 2021-12-20 2023-06-29 New Ave Pharmaceutical Inc. Bcl-2 inhibitors
WO2023122000A1 (en) * 2021-12-20 2023-06-29 Newave Pharmaceutical Inc. Bcl-2 inhibitors
US11964990B2 (en) 2022-01-21 2024-04-23 Abbvie Inc. 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors
CN116270660A (zh) * 2023-03-30 2023-06-23 广州麓鹏制药有限公司 一种含Bcl-2/Bcl-xl抑制剂的组合物及其制备方法与应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JP4336678B2 (ja) 2003-09-04 2009-09-30 株式会社日立超エル・エス・アイ・システムズ 半導体装置
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
WO2008064116A2 (en) 2006-11-16 2008-05-29 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
GB0623209D0 (en) * 2006-11-21 2007-01-03 F2G Ltd Antifungal agents
WO2009036035A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Bcl-2 inhibitors
US20090176785A1 (en) 2007-11-16 2009-07-09 Abbott Laboratories Method of treating arthritis
UA108193C2 (uk) * 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
HUE029289T2 (en) 2008-12-05 2017-02-28 Abbvie Inc Sulfonamide derivatives as Bcl-2 selective apoptosis inducers for the treatment of cancer and immune diseases
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
HUE027698T2 (en) 2009-05-26 2016-10-28 Abbvie Bahamas Ltd Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
JP5743482B2 (ja) 2010-10-15 2015-07-01 株式会社アルファ エスカッション部材のハンドルベースへの連結方法
CA3152557A1 (en) 2010-10-29 2012-05-03 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
JP6141188B2 (ja) 2010-11-23 2017-06-07 アッヴィ・インコーポレイテッド アポトーシス誘導剤の塩および結晶の形態
WO2014094357A1 (en) * 2012-12-21 2014-06-26 Abbvie Inc. Heterocyclic nuclear hormone receptor modulators
CN111960944A (zh) 2013-03-13 2020-11-20 艾伯维公司 制备细胞凋亡诱导剂的方法
CN104513259B (zh) * 2013-09-26 2017-06-16 广东东阳光药业有限公司 取代脲衍生物及其在药物中的应用
WO2017132474A1 (en) 2016-01-30 2017-08-03 Newave Pharmaceutical Inc. Bcl-2 inhibitors
US11053239B2 (en) 2017-01-07 2021-07-06 Fochon Pharmaceuticals, Ltd. Compounds as BLC-2-selective apoptosis-inducing agents
CN110546151B (zh) 2017-04-18 2023-04-28 重庆复创医药研究有限公司 凋亡诱导剂
ES2971457T3 (es) 2017-08-23 2024-06-05 Guangzhou Lupeng Pharmaceutical Company Ltd Inhibidores de BCL-2
US11903950B2 (en) 2018-08-22 2024-02-20 Newave Pharmaceutical Inc. BCL-2 inhibitors
WO2020140005A2 (en) 2018-12-29 2020-07-02 Newave Pharmaceutical Inc. Bcl-2 inhibitors

Also Published As

Publication number Publication date
AU2018321496B2 (en) 2023-11-02
AU2018321496A1 (en) 2020-04-02
IL272762B1 (en) 2023-11-01
IL272762A (en) 2020-04-30
JP7467332B2 (ja) 2024-04-15
WO2019040573A1 (en) 2019-02-28
KR102705861B1 (ko) 2024-09-10
ES2971457T3 (es) 2024-06-05
CA3073445A1 (en) 2019-02-28
JP2020531506A (ja) 2020-11-05
IL272762B2 (en) 2024-03-01
DK3672976T3 (da) 2024-03-04
EP3672976B1 (en) 2023-12-13
CN116425771A (zh) 2023-07-14
AU2018322059B2 (en) 2023-11-02
ES2948287T3 (es) 2023-09-07
CN111511748B (zh) 2023-05-02
EP3672975A1 (en) 2020-07-01
FI3672976T3 (fi) 2024-02-21
US20230271979A1 (en) 2023-08-31
FI3672975T3 (fi) 2023-06-28
MX2020002033A (es) 2020-08-20
EP3672975B1 (en) 2023-04-12
DK3672975T3 (da) 2023-07-24
CN111448198B (zh) 2023-02-03
CN111448198A (zh) 2020-07-24
JP2020531501A (ja) 2020-11-05
US20200197406A1 (en) 2020-06-25
EP3672976A1 (en) 2020-07-01
WO2019040550A1 (en) 2019-02-28
US20220402941A1 (en) 2022-12-22
US11365206B2 (en) 2022-06-21
US20200190109A1 (en) 2020-06-18
CN111511748A (zh) 2020-08-07
KR20200090738A (ko) 2020-07-29
KR20200092308A (ko) 2020-08-03
CN116621860A (zh) 2023-08-22
EP4227311A1 (en) 2023-08-16
US11680072B2 (en) 2023-06-20
KR102680163B1 (ko) 2024-06-28
SG11202001553UA (en) 2020-03-30
US20220220126A1 (en) 2022-07-14
US11279711B2 (en) 2022-03-22
JP7467331B2 (ja) 2024-04-15
CA3073446A1 (en) 2019-02-28
AU2018322059A1 (en) 2020-04-02
AU2018322059C1 (en) 2024-09-12
US11993610B2 (en) 2024-05-28

Similar Documents

Publication Publication Date Title
MX2020002032A (es) Inhibidores de bcl-2.
WO2017132474A8 (en) Bcl-2 inhibitors
WO2020041405A8 (en) Bcl-2 inhibitors
MX2021007576A (es) Nuevo anticuerpo anti receptor 8 de motivo c-c de quimiocina (ccr8).
WO2021066873A8 (en) Condensed heterocycles as bcl-2 inhibitors
MX2021001706A (es) Compuestos de anillo fusionado.
MX2020008627A (es) Inhibidores de btk y mutantes de los mismos.
IL282468A (en) 2-Amino-n-heteroaryl-nicotinamides as inhibitors of nav1.8
PH12020500655A1 (en) Compounds
WO2018042343A3 (en) Compounds that inhibit 3c and 3cl proteases and methods of use thereof
AU2017382297A8 (en) Phosphodiesterase inhibitors and methods of microbial treatment
SG11201909186YA (en) Triazole silane compound, method for synthesizing said compound and use thereof
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
GEP20227443B (en) Magl inhibitors
MX2021012973A (es) Sustituto de huevo y composiciones que comprenden el sustituto de huevo y metodos para producir el mismo.
EA202193015A1 (ru) Ингибиторы cdk
SG11201906435SA (en) Pyrimidine compound and pharmaceutical use thereof
MX2019011116A (es) Inhibidores de la tirosina quinasa de bruton.
MX2020012990A (es) Formulaciones de tegavivint y compuestos relacionados.
EA202092540A1 (ru) Комбинации для лечения рака
ZA202211980B (en) Methods and treatment of trauma
EA202090933A1 (ru) Способ получения гербицидных соединений пиридазинона
EA201992302A1 (ru) Соединения, используемые в качестве ингибиторов alcat1
MX2020010655A (es) Metodo para la preparacion de una 1,2,4-triazolona 2,4,5-trisustituida.
PH12020500674A1 (en) New isoxazolyl ether derivatives as gaba a alpha5 pam

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: GUANGZHOU LUPENG PHARMACEUTICAL COMPANY LTD.